Chronic Venous Insufficiency Clinical Trial
— ReLeafOfficial title:
A Feasibility Study of the InterVene ReLeaf Catheter System in the Creation of Tissue Leaflets in the Femoral and/or Popliteal Vein
Verified date | March 2018 |
Source | Intervene, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is designed to evaluate the safety and technical feasibility of the ReLeaf Catheter System in the creation of one or more tissue leaflets in the femoral and/or popliteal vein in subjects with chronic venous insufficiency and who meet the protocol entry criteria.
Status | Terminated |
Enrollment | 2 |
Est. completion date | June 5, 2017 |
Est. primary completion date | October 8, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - History of symptomatic chronic venous insufficiency subjects, clinical category CEAP 3 or greater. - History of failed compression therapy (of at least 6 months), combined with superficial venous or perforator surgery. - Femoral and/or popliteal venous reflux of = 1.0 seconds. - Deep system reflux with Kistner classification grade 2 or higher. - 18 years of age or older at the time of consent. - Willing and able to sign the Ethics Committee (EC) approved informed consent form. - Willing to comply with follow-up evaluations and protocols. Exclusion Criteria: - In the Investigator's opinion, venous outflow obstruction that would inhibit adequate flow away from valve site. - Obstructive features in the femoral or popliteal vein below the proposed tissue leaflet creation site, which, in the Investigator's opinion, will not allow for sufficient blood flow to the tissue leaflet creation site. - Deep venous system intervention within 6 months of consent. - Obstructive features or irregularly small luminal diameter in the femoral vein which, in the opinion of the Investigator, will prohibit access to a tissue leaflet creation site. - Prior deep vein valve surgical intervention in the ipsilateral limb. - Ankle arthrodesis with secondary muscle atrophy or severely limited ambulation. - Limb-threatening circulatory compromise. - Contraindications to anticoagulation therapy that cannot be medically controlled. - History of symptomatic pulmonary embolism. - Acute venous thromboembolism within 3 months of consent. - Comorbidity risks which, in the opinion of the Investigator, limit longevity or likelihood of complying with protocol follow up. - General contraindications to surgery or the use of anesthesia. - Uncontrolled heart failure, or NYHA Class III or IV heart failure. - Open Cardiac surgery (e.g. ventriculotomy, atriotomy) within the past 6 months of consent (Interventional procedures such as stenting or PTCA do not apply.) - Chronic Kidney Disease with creatinine level of 2mg/dL or higher. - Active systemic infection or sepsis. - Pregnant or lactating (positive pregnancy test, women of childbearing potential must be tested). - Appropriate vascular access is precluded. - Subject is enrolled in any other clinical study that, in the opinion of the Investigator, may conflict with this study or compromise study results. - Subject is considered at high risk for non-compliance with the protocol (e.g., inaccessible for follow-up). - Other invasive surgical procedure within the last 90 days that in the Investigator's opinion would interfere with the study procedure or results. - History of stroke within the last 6 months. - Subject is incarcerated or will be incarcerated during the course of the study. - Untreated significant superficial venous incompetence |
Country | Name | City | State |
---|---|---|---|
New Zealand | Auckland City Hospital | Auckland |
Lead Sponsor | Collaborator |
---|---|
Intervene, Inc. |
New Zealand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Efficacy | Subsequent efficacy of the treatment following successful creation of the tissue leaflet(s). This will be measured through an assessment of tissue leaflet creation and the tissue leaflets ability to impact blood flow over the course of time. | Day 365 | |
Other | Durability | Long-term durability of the tissue leaflet(s). Confirmation of tissue leaflet existence over time will be used to assess the durability of the tissue leaflet. | Day 365 | |
Other | Long-term Safety (Long-term safety will be measured by freedom from SAEs directly attributable to the study device) | Further long-term safety data will be collected, analyzed and reported through the end of the study. Long-term safety will be measured by freedom from SAEs directly attributable to the study device. | Day 365 | |
Primary | Technical Feasibility | Technical feasibility will be evaluated as the ability of the ReLeaf Catheter System to access the target site and successfully modify tissue as confirmed by, and in the opinion of, the Investigator. Successful target site access and confirmed tissue modification will be used as a measure of technical feasibility. | Day 0 | |
Primary | Safety (The number of SAEs directly attributable to the study device will be used as a measure of safety) | Safety will be evaluated as freedom from serious adverse events directly attributed to the investigational device. The number of SAEs directly attributable to the study device will be used as a measure of safety. | Day 30 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05504070 -
Venclose digiRF System Post Market Study
|
N/A | |
Completed |
NCT05507346 -
A Clinical Study to Evaluate the Effectiveness of a Novel Portable Non-Pneumatic Active Compression Device vs. an Advanced Pneumatic Compression Device for Treating Lower Extremity Lymphedema
|
N/A | |
Recruiting |
NCT05622500 -
Best Endovenous Treatment, Including STenting, Versus Non-endovenous Treatment in Chronic Proximal Deep Venous Disease
|
N/A | |
Completed |
NCT03283800 -
Copper Impact on Venous Insufficiency and Lipodermatosclerosis
|
N/A | |
Terminated |
NCT02248740 -
Radiofrequency Ablation vs. Laser Ablation of the Incompetent Small Saphenous Vein
|
Phase 4 | |
Completed |
NCT01501188 -
Efficacy Study of Kinesio Taping to Treat Muscular and Joint Problems in Chronic Venous Insufficiency
|
Phase 1 | |
Completed |
NCT02236338 -
Radiofrequency Ablation vs Laser Ablation of the Incompetent Greater Saphenous Vein
|
Phase 4 | |
Recruiting |
NCT05982405 -
Long-term Effects of Inspiratory Muscle Training in Chronic Venous Insufficiency
|
N/A | |
Completed |
NCT05383469 -
Efficacy of Active Versus Passive Methods in Chronic Venous Insufficiency
|
N/A | |
Completed |
NCT06238791 -
Plantar Pressure Analysis and Foot Biomechanics in Lipedema and Chronic Venous Disease
|
||
Withdrawn |
NCT02559427 -
SPA Therapy in the Treatment of Sleep Apnea Syndrome
|
N/A | |
Completed |
NCT02346058 -
Efficacy and Safety of Esarin Gel in Chronic Venous Insufficiency and Varicose Veins
|
Phase 4 | |
Active, not recruiting |
NCT05926830 -
Extracorporeal Flow Abolition in Relation With Primary Insufficiency of Great Saphenous Veins (GSV) Using High Intensity Focused Ultrasound (HIFU) Generated by Sonovein: A Multi Center Prospective Pivotal Study
|
N/A | |
Withdrawn |
NCT05047302 -
Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System-Canada
|
N/A | |
Active, not recruiting |
NCT04339075 -
Registry to Investigate the Efficacy and Safety of VenaBlock VeIn SEaling System for VaRicose Veins in SingApore
|
||
Active, not recruiting |
NCT04580160 -
Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System
|
N/A | |
Not yet recruiting |
NCT02927483 -
Study to Assess the Efficacy and Safety of Endolex Forte VErsus Diosmin and Hesperidin in Reducing VeNous Insufficiency
|
Phase 3 | |
Completed |
NCT02015221 -
Evaluation of a Dual Action Pneumatic Compression Device: Patient Ease of Use and Comfort
|
N/A | |
Completed |
NCT02050061 -
Chronic Venous Insufficiency; Impact of Compression Stockings on Quality of Life
|
N/A | |
Completed |
NCT01432795 -
Practicability of Gliding Aids for Medical Compression Stockings
|
Phase 4 |